News

Utilization and costs of novel DMD therapies has risen rapidly in recent years, raising questions about affordability and equitable access

Patients with Duchenne muscular dystrophy may benefit from a potential therapy now supported by an FDA orphan designation.

The ability to keep the torso upright, known as trunk control, might decline even while boys with DMD are still able to walk

Half of boys with Duchenne muscular dystrophy had vertebral fractures, many of which happened silently without obvious trauma.

Transaminitis with no signs of liver dysfunction may signal DMD long before visible weakness or motor delays present, study suggests.

Many patients with DMD can live well into adulthood using continuous noninvasive breathing support combined with cough-assist devices.

In a one-year trial, del-zota helped boys with DMD gain strength and function, reversing their expected decline.

Children with DMD experience steady bone loss as they age and continue steroid treatment, raising concerns for long-term mobility.

A survey found that most DMD caregivers would choose a therapy with variable outcomes even if there was a risk of earlier loss of ambulation.

A recent study identified many severe comorbidities in patients with DMD, including gastrointestinal, cardiovascular and kidney conditions.